Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

UBS upgrades Weir to 'buy', shares rally

(Sharecast News) - Weir Group shot higher on Thursday after UBS upgraded the shares to 'buy' from 'neutral' and hiked the price target to 2,850p from 2,250p. The bank said its new 'buy' thesis is driven mostly by its view that there is significant upside to the savings that Weir can achieve from its Performance Excellence plan.

"However, we also think Weir is the best protected amongst peers in the event of a downturn following recent tariffs," it added.

UBS noted that Weir has built up a track record for under promising and overdelivering. It pointed out that since the Performance Excellence programme was announced in September 2022, the cost savings guidance has been increased twice.

The initial target was £30m. This was then revised up to £60m in 2023 and £80m in 2024.

"We think Weir can generate significantly more cost savings than guided," UBS said.

Using bottom up analysis, UBS estimated that Weir can generate £125m of savings from its Performance Excellence programme versus guidance of £80m by the end of 2026.

The additional £45m is equivalent to an incremental +1.6% adjusted EBITA margin in 2026.

"We estimate an adjusted EBITA margin of 23.4% in 2026, which is significantly above consensus at 20.4%," UBS said.

The bank thinks the market is currently pricing in £80m of cost savings.

"What's driving our above guidance estimates? We have performed bottom up analysis on Weir's cost savings programme to formulate a total savings estimate.

"The key sources of difference versus guidance come from 1) Weir Business Services, where we estimate that Weir can deliver £55m savings versus guidance of £20m, and 2) £40m of savings from capacity optimisation versus guidance of £30m."

In its upside scenario, UBS sees scope for £200m of savings from the programme.

The bank said that overall, it thinks the impact from tariffs will potentially be limited.

"Even in a worst case scenario, we calculate (based on our assumptions) that Weir's idiosyncratic cost savings programme is likely large enough for Weir to deliver consensus earnings in 2026."

At 0935 BST, the shares were up 3.3% at 2,386p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.